Drug Update · Endocrinology

FDA Approves denosumab-adet (Ponlimsi) as Interchangeable Biosimilar to Prolia

August 19, 2026

FDA approval timing

March 2026

Approved dose

60 mg every 6 months subcutaneous

Calcium and vitamin D

Calcium 1,000 mg daily; at least 400 IU vitamin D daily

REMS requirement

REMS required for severe hypocalcemia in advanced CKD

U.S. License No.

2325

Dating period

36 months from date of manufacture when stored at 5 ± 3°C

Contraception duration

Use effective contraception during therapy and for at least 5 months after last dose

Clinical Perspective

This approval affects clinicians treating postmenopausal women with osteoporosis at high risk for fracture; men with osteoporosis at high risk for fracture; patients with glucocorticoid-induced osteoporosis; men receiving androgen deprivation therapy for nonmetastatic prostate cancer; and women receiving adjuvant aromatase inhibitor therapy for breast cancer, who now have Ponlimsi as an FDA‑licensed biosimilar and interchangeable product to Prolia ^[1]^[2]. The labeled dosing for Ponlimsi is 60 mg administered subcutaneously once every 6 months, and the approval includes a REMS focused on severe hypocalcemia risk in advanced CKD, which will influence pre-treatment evaluation and education ^[1]^[2]. How REMS-driven communications and interchangeability designations will affect prescribing workflows and monitoring for hypocalcemia in advanced CKD patients remains to be characterized?

Dr. Amit Desai, MBBS, MD (General Medicine), DM (Endocrinology) · Endocrinology

Ponlimsi (denosumab-adet) was approved by the U.S. Food and Drug Administration in March 2026 as a biosimilar to Prolia (denosumab) and licensed for marketing to Teva Pharmaceuticals, with interchangeability to the U.S.-licensed Prolia noted in the approval documents ^[2]^[3]. The approval covers multiple labeled osteoporosis and bone-loss indications and includes a Risk Evaluation and Mitigation Strategy (REMS) for risk of severe hypocalcemia in patients with advanced chronic kidney disease ^[2]^[1].

Clinical Context

Ponlimsi (denosumab-adet) is a RANK ligand (RANKL) inhibitor marketed as a biosimilar to Prolia, intended for subcutaneous administration in a single-dose prefilled syringe ^[1]^[2]. The BLA for Ponlimsi was submitted under section 351(k) of the Public Health Service Act and the license authorizes manufacture and interstate commerce of Ponlimsi by Teva Pharmaceuticals, Inc. Manufacturing sites and stability/dating provisions were specified in the approval ^[2]. The FDA listing of biosimilar products includes Ponlimsi among products approved in March 2026 ^[3]. The approval letter requires a REMS with a communication plan to mitigate the risk of severe hypocalcemia in patients with advanced chronic kidney disease, including dialysis-dependent patients ^[2].

Key Findings

The FDA has approved Ponlimsi (denosumab-adet) as a biosimilar to and interchangeable with U.S.-licensed Prolia, authorizing manufacture and marketing under U.S. License No. 2325 to Teva Pharmaceuticals, Inc. ^[2].
Ponlimsi is indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture; to increase bone mass in men with osteoporosis at high risk for fracture; treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture; to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer; and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ^[1]^[2].
The approval includes a REMS to address severe hypocalcemia in patients with advanced chronic kidney disease, and the REMS must be fully operational before commercial distribution ^[2].
The prescribing information for Ponlimsi notes biosimilarity to Prolia for the conditions of use, dosing regimen, strength, dosage form, and route of administration described in the Full Prescribing Information ^[1].

Safety & Tolerability

WARNING: Severe hypocalcemia in patients with advanced chronic kidney disease, including dialysis-dependent patients; severe hypocalcemia resulting in hospitalization, life-threatening events, and fatal cases have been reported ^[1].
The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases risk of hypocalcemia; evaluate for CKD-MBD prior to initiating Ponlimsi in patients with advanced CKD ^[1].
Pre-existing hypocalcemia is a contraindication; correct hypocalcemia before initiating Ponlimsi ^[1].
Patients receiving Ponlimsi should not receive other denosumab products concomitantly ^[1].
Hypersensitivity, including anaphylactic reactions, may occur; discontinue permanently if clinically significant ^[1].
Osteonecrosis of the jaw has been reported with denosumab products ^[1].
Atypical femoral fractures have been reported; evaluate patients with thigh or groin pain to rule out femoral fracture ^[1].
Multiple vertebral fractures have been reported following treatment discontinuation; patients should be transitioned to another antiresorptive agent if Ponlimsi is discontinued ^[1].
Serious infections, including skin infections that may lead to hospitalization, have been reported ^[1].
Dermatologic reactions such as dermatitis, rashes, and eczema have been reported ^[1].
Severe bone, joint, or muscle pain may occur; discontinue if severe symptoms develop ^[1].
Suppression of bone turnover has been demonstrated; monitor for consequences of bone over-suppression ^[1].
Reported adverse reactions in clinical trials for postmenopausal osteoporosis (>5% and more common than placebo) included back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis ^[1].
Additional reported adverse reactions across specified indications include arthralgia, nasopharyngitis, hypertension, bronchitis, headache, and pancreatitis in clinical trials ^[1].

Study Design

Ponlimsi was approved under a BLA submitted under section 351(k) of the Public Health Service Act seeking licensure as a biosimilar and interchangeable product to U.S.-licensed Prolia; U.S. License No. 2325 was issued to Teva Pharmaceuticals, Inc. ^[2]. The approval letter and prescribing information specify labeled indications, dosing, manufacturing locations, and REMS requirements ^[1]^[2]. Details of the comparative clinical studies supporting biosimilarity were referenced in the prescribing information but specific trial names, primary efficacy numerical results, and full study design elements were not available in the provided source excerpts ^[1]^[2].

FAQ

Q1 What is Ponlimsi (denosumab-adet) approved for?

Ponlimsi is approved for treatment of postmenopausal women with osteoporosis at high risk for fracture; to increase bone mass in men with osteoporosis at high risk for fracture; treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture; to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer; and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Q2 How does Ponlimsi work?

Ponlimsi is a RANK ligand (RANKL) inhibitor; it binds to RANKL and blocks its ability to bind to the RANK receptor, inhibiting the RANKL/RANK interaction that contributes to osteoclast-mediated bone resorption. The prescribing information states Ponlimsi is biosimilar to Prolia and that biosimilarity has been demonstrated for the conditions of use, dosing regimen, strength, dosage form, and route of administration described in its Full Prescribing Information.

Q3 What is the recommended dose of Ponlimsi?

The recommended dosage of Ponlimsi is 60 mg administered as a single subcutaneous injection once every 6 months via the upper arm, upper thigh, or abdomen; Ponlimsi is supplied as a 60 mg/mL solution in a single-dose prefilled syringe. The label instructs healthcare providers to ensure pregnancy is ruled out prior to administration in females of reproductive potential and to recommend calcium 1,000 mg daily and at least 400 IU vitamin D daily. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the most common side effects?

The prescribing information lists adverse reactions observed in clinical trials; for postmenopausal osteoporosis the most common adverse reactions (>5% and more common than placebo) included back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Other reported events across indications include arthralgia, nasopharyngitis, hypertension, bronchitis, headache, pancreatitis, osteonecrosis of the jaw, atypical femoral fractures, serious infections including skin infections, dermatologic reactions, severe bone/joint/muscle pain, and suppression of bone turnover. Severe hypocalcemia, particularly in patients with advanced chronic kidney disease, is emphasized as a boxed warning and contraindications and monitoring recommendations are provided in the Full Prescribing Information.

Clinicians should consult current prescribing information for full dosing guidance.

FDA Approves denosumab-adet (Ponlimsi) as Interchangeable Biosimilar to Prolia

Direct Clinical Takeaway & Evidence Summary

FDA Approves denosumab-adet (Ponlimsi) as Interchangeable Biosimilar to Prolia

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Endocrinology in your inbox.

Related Clinical Updates

Orforglipron (FOUNDAYO) FDA Approved for Obesity; 11.2% vs 2.1% Mean Weight Change in ATTAIN-1

GLP-1 Receptor Agonists Beyond Glycemia: Cardiovascular, Weight and Mechanistic Evidence for Clinicians

FDA Proposes 503B Exclusion for Semaglutide, Tirzepatide, Liraglutide

Verified HCP Portal